Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CVS HEALTH CORPORATION

(CVS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CVS HEALTH CORP : Change in Directors or Principal Officers (form 8-K)

06/10/2021 | 05:22pm EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.





(e) On May 18, 2021, CVS Health Corporation ("CVS Health", and together with its subsidiaries, the "Company") announced that Eva C. Boratto, former Executive Vice President - Chief Financial Officer of CVS Health, would be stepping down from that role effective May 28, 2021. At the Company's request to assist in transition and for strategic support, Ms. Boratto has agreed to remain with the Company in a senior advisory role to CVS Health's President and Chief Executive Officer Karen S. Lynch through no later than December 1, 2021 (such date, the "Separation Date").

On June 9, 2021, CVS Pharmacy, Inc., a wholly-owned subsidiary of CVS Health, entered into an agreement (the "Agreement") with Ms. Boratto to memorialize the terms of her continued service and the parties' mutual agreement to separate. Under the Agreement, the Company has agreed to provide Ms. Boratto with 22 months of continued base salary following the Separation Date (the "Salary Continuation Period"). Ms. Boratto's stock options will continue to vest and remain exercisable for up to three-years following the Separation Date. Her restricted stock unit award will continue to vest through the end of the Salary Continuation Period and be settled on the original vesting date, and her outstanding performance stock unit awards will vest on a pro-rated basis through the Separation Date and be settled on their original vesting dates. Under the Agreement, Ms. Boratto also is entitled to a pro-rated bonus for performance year 2021 based on Company performance and reimbursement of certain expenses in the amount of up to $90,000 in connection with the transition.

The Agreement also contains a release of claims against the Company, with customary confidentiality and cooperation covenants, and incorporates by reference any other covenants to which Ms. Boratto already is subject, including the non-competition and non-solicitation covenants set forth in her restrictive covenant agreement, as amended pursuant to the Agreement.

© Edgar Online, source Glimpses

All news about CVS HEALTH CORPORATION
07/28CVS HEALTH : opens Workforce Innovation and Talent Center in Pittsburgh
PU
07/22CVS HEALTH CORPORATION : Ex-dividend day for
FA
07/21FACTBOX-Companies pay billions of dollars over role in U.S. opioid crisis
RE
07/21CVS HEALTH CORPORATION : to Hold Second Quarter 2021 Earnings Conference Call
PR
07/21Drugmakers, pharmacies next targets for U.S. opioid settlements
RE
07/20New York, drug distributors reach $1.18 billion opioid settlement as national..
RE
07/16WALGREENS BOOTS ALLIANCE : Target removes J&J sunscreens from stores, website
RE
07/15Pharmacies pull J&J sunscreens off shelves after carcinogen found in some spr..
RE
07/15MARKET CHATTER : CVS Health Reportedly Halts Sales of Sun-Care Products After J&..
MT
07/14Over two million Americans sign up for Obamacare under Biden drive
RE
More news
Financials (USD)
Sales 2021 282 B - -
Net income 2021 8 233 M - -
Net Debt 2021 48 413 M - -
P/E ratio 2021 13,4x
Yield 2021 2,41%
Capitalization 109 B 109 B -
EV / Sales 2021 0,56x
EV / Sales 2022 0,52x
Nbr of Employees 256 500
Free-Float 75,6%
Chart CVS HEALTH CORPORATION
Duration : Period :
CVS Health Corporation Technical Analysis Chart | CVS | US1266501006 | MarketScreener
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 83,06 $
Average target price 95,94 $
Spread / Average Target 15,5%
EPS Revisions
Managers and Directors
Karen S. Lynch President, Chief Executive Officer & Director
Shawn M. Guertin Chief Financial Officer & Executive Vice President
David Wyatt Dorman Chairman
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Jonathan C. Roberts Chief Operating Officer & Executive Vice President